Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aG...
September 03 2020 - 9:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a
clinical-stage global developer of cell-based technologies and
therapeutics, today announced the launch of its new allogeneic
mesenchymal stromal cell (MSC) therapeutic platform. Avalon plans
to develop the MSC platform as a potential therapy for COVID-19,
the disease caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), and for bone marrow transplant related
complications of acute graft versus host disease (aGVHD).
Mesenchymal stromal cells are typically isolated from the bone
marrow, umbilical cord blood, fat tissue and other tissue types.
MSCs possess unique qualities including anti-inflammatory and
immunomodulatory activities. MSCs have multiple functions
within the immune system, affecting many different immune cell
types. MSCs have the ability to suppress T-cell proliferation,
cytokine secretion and regulate the balance of antibody-based and
cell-based immune responses. MSCs are capable of inhibiting the
activation of dendritic cells and blocking the ability of dendritic
cells to present antigens to other cells in the immune system. MSCs
can also tone down the abnormal release of either antibodies from
B-cells or cytokines from natural killer cells.
Avalon’s MSC therapeutic platform represents the culmination of
extensive research and development that leverages the Company’s
scientific and clinical expertise in cellular therapy and stem
cell-derived exosome (ACTEXTM) applications. Avalon believes that
this allogeneic MSC platform could offer a unique and efficacious
approach to treat the potentially fatal acute respiratory distress
syndrome, multi-system inflammatory syndrome and cytokine storm
related to severe cases of COVID-19.
Accumulating evidence has revealed that aberrant and excessive
immune responses evoked by a SARS-CoV-2 virus infection are
involved in lung damage and multi-organ injury seen in some
patients with moderate and severe COVID-19. Also involving an
excessive immune assault on multiple organs and tissues, including
the gut, liver and skin, aGVHD is a medical complication that is
potentially life-threatening and commonly seen in allogeneic bone
marrow transplantation. There are currently no effective
therapies for the prevention and treatment of aGVHD.
The Company is currently progressing its planned pre-clinical
testing for its MSC therapeutic platform for COVID-19 and aGVHD,
with plans to initiate a first-in-human clinical study during the
first half of 2021, assuming clearance from U.S. and/or non-U.S.
regulatory agencies.
“Taking advantage of our expertise in cellular therapy
development, we are encouraged by the rapid progress we have made
in moving our MSC technology platform towards the clinic for these
two important indications,” stated David Jin, M.D., Ph.D.,
President and Chief Executive Officer of Avalon. “We look forward
to providing updates on our advancements.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
vertically integrated, leading CellTech bio-developer dedicated to
advancing and empowering innovative, transformative immune effector
cell therapy, exosome technology, as well as COVID-19 related
diagnostics and therapeutics. Avalon also provides strategic
advisory and outsourcing services to facilitate and enhance its
clients' growth and development, as well as competitiveness in
healthcare and CellTech industry markets. Through its
subsidiary structure with unique integration of verticals from
innovative R&D to automated bioproduction and accelerated
clinical development, Avalon is establishing a leading role in the
fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX™), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments,
please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Sep 2023 to Sep 2024